TABLE 1.
Topical beta‐blockers off‐label use in dermatologic diseases
| Disorder | Preferred topical beta blocker | Most widely used concentration | Frequency of administration | Treatment duration |
|---|---|---|---|---|
| Infantile hemangiomas (IHs) | Timolol16 | 0.5% | Twice daily | 6–9 months |
| Propranolol12 | 1% | Twice daily | 6–9 months | |
| Pyogenic granuloma | Timolol27 | 0.5% | Twice daily | 2 months |
| Propranolol28, 29, 30 | 1%–4% | Twice daily | 2 months | |
| Nail paronychia | Timolol31 | 0.5% (under occlusion) | Twice daily | 1 months |
| Kaposi sarcoma | Timolol33, 34, 35, 36 | 0.5% (some reports with 0.1%)73 | Twice daily | 3 months |
| Wound | Timolol37, 38, 39, 40 | 0.5% (1 drop/2 cm) | Once daily | 3 months |